STUDENTS: Apply here for a 2021 PCF/PMIC Scholarship!

Through the generosity of the Pharmacists Mutual Insurance Company, the Pharmacy Compounding Foundation will award up to two $2,500 scholarships in 2021 to pharmacy students who have demonstrated commitment to a career in compounding pharmacy in the United States.

Details of the EduCon schedule will be available soon, but the deadline to apply for the scholarship is January 8, 2021. Email foundation@a4pc.org with questions.

Click here to apply for the Pharmacy Compounding Foundation and Pharmacists Mutual Insurance Company Compounding Scholarship.

Dates set for 2021 EduCon, Owner Summit

Mark your calendars!

EduCon Virtual 2021: Best Practices in Compounding will be held, well, virtually on February 4 – 5, 2021. More info to follow, of course.

And pharmacy owners and managers will want to plan on APC’s inaugural 2021 Compounding Pharmacy Owner Summit — March 26-27, 2021 at the Westin Jekyll Island on Jekyll Island, Georgia

Registration for both events will open soon.

Passionate about state-level compounding issues?

To grow our influence and effectiveness on state-level legislative and regulatory issues, the APC Board has approved the formation of a State Legislative & Regulatory Committee for 2021.

Incoming President Michael Blaire is looking to appoint to that committee APC members who are passionate and informed about state-level public policy affecting compounding. The committee is expected to meet quarterly in 2021 via teleconference.

*If you have interest in serving, shoot an email to info@a4pc.org before Wednesday, December 23, 2020.

Reminder: Help us get cBHT data from your prescribers

As part of our effort to save cBHT, APC is helping to gather evidence from physicians that supports its safety and efficacy of cBHT.

We have developed a brief survey on Google Forms, which will take no more than five minutes for your physicians to fill out: Compounded Hormones for Female Patients is a survey assessment of prescribing habits and methods used to evaluate the safety and efficacy of female compounded hormones. This survey includes an invitation to contribute with potential case studies for scientific publication.

Please ask the physicians you work with to participate (by February 15, 2021). The kind of real data it will help us catalog will be vital in establishing the safety and efficacy of cBHT.

The link to the survey is A4PC.org/cbhtsurvey.

Together we can save cBHT.

Board approves cBHT policy

The APC Board of Directors has approved the alliance’s official policy statement on compounded bio-identical hormone therapy.

Highlights of the statement:

Click here to read the full statement, and visit A4PC.org/cbht for all our latest information on the fight to protect cBHT.

SCOTUS ruling: Huge win for indy pharmacies

This is a major announcement from the U.S. Supreme Court — it ruled 8-0 (!) in favor of the state of Arkansas — and against PBMs — in Rutledge v. Pharmaceutical Care Mgmt Assoc. You can read the full ruling (PDF) here.

Out of the loupe? SCOTUS has said, essentially, that yes, states can regulate PBMs. The PBMs had argued (so far successfully) that the federal ERISA law preempted state regulations. Any state regs, they said, were automatically tied to ERISA and thus pre-empted by it.

‘Nuh-uh,’ said the Supremes: “The Court holds that the Act [the Arkansas law] has neither an impermissible connection with nor reference to ERISA and is therefore not pre-empted.”

On-demand CE, so you don’t miss a thing

Did you miss our webinar on the truth about peptides compounding? Or maybe e-prescribing? No worries: APC’s got you covered with our on-demand CE archive of those courses and more, just for compounders.

If you’re looking for a particular class — or just to top off your CE requirements — don’t settle for same-old, same-old content. Visit A4PC.org/cearchive and check out our lineup of great self-paced classes covering hot topics like peptides, shortage compounding, cBHT, smart accreditation, and much more.

That’s A4PC.org/cearchive — check out what you can learn today!

Your cBHT business is at risk. Here’s how to confront it.

If you compound hormones for patients, you need to be worried — and so do they. The FDA has said it will consider restricting or even eliminating cBHT based on a faulty research study.

This is an existential threat for the compounding industry, and potentially a nightmare for the millions of Americans who rely on cBHT therapy. It will require an ambitious, long-term, and nationwide effort to stop it.

The Alliance for Pharmacy Compounding, with your help, is stepping up to protect your business and your patients.

The plan

We’re planning a three-year, multi-pronged campaign to focus not on statistics, but on the human face of compounded hormone therapy: the patients it helps.

What do we mean by “a human face”? We’ll show you. Check out this proof-of-concept video for a feel of the campaign’s tone:

image-20201208092859932

APC is planning a nationwide electronic, print, and video effort targeted at the people who can make a difference. (Here’s a three-page brief on the campaign.)

We’ve already laid the groundwork with an independent analysis of the flawed NASEM study at the heart of FDA’s excuses (generously funded by the Pharmacy Compounding Foundation and available early next year). We’re also collecting testimonials about the human value of cBHT on our portal (A4PC.org/cbhtandme) — we have more than 2,400 so far, but we need at least twice that.

Both of these will provide helpful information — ammunition, if you will — for the fight ahead. But they aren’t nearly enough.

The budget

This must be a tremendous effort — we need to raise $250,000 by the end of December for development and testing of the print, electronic, and video ads for a launch in February 2021. The full rollout will need $3 million over three years. In fact, we have already raised more than $120,000.

But the question isn’t how much it will cost. The question is: What will happen to your business and your patients if you cannot compound hormone therapy?

Right now

Please, take a moment and join your colleagues as a part of the solution — protect your patients and protect your business before restrictions take effect.

This is more than a contribution. It’s an investment in the future of your compounding practice and the ability to provide patients with the compounded hormones they need.

Thank you. If you have any other questions, we’d be happy to answer. Drop a note to APC staff at info@a4pc.org or call us at (281) 933-8400. And for more information on the threat to cBHT and what APC is doing, visit A4PC.org/cbht.

Covid-19 vaccine billing guidance is available

With the first Covid-19 vaccine just around the corner, now’s the time to get your ducks in a row if you’re planning to provide vaccinations.

NCPDP has released its guidance for providing the vaccine (22-page PDF: https://fllw.me/2JTmiUO), but you probably want to start with NCPA’s overview for how you’re likely to need to bill for the vaccine: https://fllw.me/37IsJ5h.

We’ve got some friends in Congress coming to our aid to preserve compounded hormone therapy

Four representatives — Jaime Herrera Beutler, Henry Cuellar, Mark Pocan, and David P. Roe, M.D. — have written a letter to FDA Commissioner Stephen Hahn expressing their concern with the NASEM report. That’s the FDA-commissioned “study” that suggested limiting the availability of cBHT, despite the fact that it is used successfully by millions of people.

“[W]e ask the agency to consider the severely negative impact some of NASEM’s recommendations would have on patients,” they wrote, laying out some of the very issues APC has been pointing out since the NASEM report came out.

Their top point: “Doctors and patients should decide the best therapy.” It’s that simple (although we would add “pharmacists” to that list).

WE NEED YOU: Ask YOUR member of Congress to sign on to the letter. A phone call or message, “Please sign the Pocan letter to FDA about compounded hormone therapy” can make a difference.

Read the Pocan et al letter itself here.

Read APC’s brief on the issue here.

Older Entries »